Biocon Presentations & Investor Relations material

Biocon Ltd. is India's premier biopharma enterprise focused on innovation to deliver affordable healthcare solutions to patients, partners and healthcare systems across the globe. Established in 1978 by Ms. Kiran Mazumdar-Shaw, Biocon is committed to reducing the treatment costs of chronic diseases such as diabetes, cancer and autoimmune diseases. Biocon's key innovations include the world's first Pichia-based recombinant human insulin, INSUGEN®, insulin analogue Glargine, BASALOG®, and India's first indigenously produced monoclonal antibody, BioMAb EGFR®, for head & neck cancer. INSUPen® is a next generation affordable insulin delivery device introduced in India by Biocon. Continuing its commitment to affordable innovation, Biocon has delivered its second novel biologic drug, Biomala, a 'first in class' biotechnological antibody, and the world's only bio-analytic monoclonal insulin therapy costs. Biocon's key innovations include the world's first Pichia-based recombinant human insulin,